SELLAS Life Sciences Group (SLS) Common Equity: 2011-2024
Historic Common Equity for SELLAS Life Sciences Group (SLS) over the last 9 years, with Sep 2024 value amounting to $15.9 million.
- SELLAS Life Sciences Group's Common Equity rose 515.26% to $15.9 million in Q3 2024 from the same period last year, while for Sep 2024 it was $15.9 million, marking a year-over-year increase of 515.26%. This contributed to the annual value of -$8.0 million for FY2023, which is 264.42% down from last year.
- As of Q3 2024, SELLAS Life Sciences Group's Common Equity stood at $15.9 million, which was up 445.55% from $2.9 million recorded in Q2 2024.
- In the past 5 years, SELLAS Life Sciences Group's Common Equity registered a high of $33.4 million during Q2 2021, and its lowest value of -$8.0 million during Q4 2023.
- Moreover, its 3-year median value for Common Equity was $4.9 million (2022), whereas its average is $6.8 million.
- In the last 5 years, SELLAS Life Sciences Group's Common Equity skyrocketed by 783.29% in 2021 and then crashed by 264.42% in 2023.
- Quarterly analysis of 5 years shows SELLAS Life Sciences Group's Common Equity stood at $28.0 million in 2020, then fell by 27.23% to $20.3 million in 2021, then tumbled by 76.16% to $4.9 million in 2022, then crashed by 264.42% to -$8.0 million in 2023, then soared by 515.26% to $15.9 million in 2024.
- Its Common Equity was $15.9 million in Q3 2024, compared to $2.9 million in Q2 2024 and $9.7 million in Q1 2024.